Novartis AG (NOVNZ.XC)
| Previous close | 92.57 |
| Open | 93.10 |
| Bid | 93.25 x 0 |
| Ask | 93.27 x 0 |
| Day's range | 93.10 - 93.85 |
| 52-week range | 79.19 - 94.52 |
| Volume | |
| Avg. volume | 540,351 |
| Market cap | 190.513B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 23.36 |
| EPS (TTM) | 3.99 |
| Earnings date | 18 July 2024 |
| Forward dividend & yield | 3.30 (3.54%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
GlobeNewswireNovartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the initial acceptance period is expected to occur on 23 May 2024Additional statutory acceptance period is expected to end on 30 May 2024 at 24:00 hours CESTTransaction strengthens the Novartis pipeline in oncology, adding pelabresib, a late-stage BET inhibitor for myelofibrosis and tulmimetostat, an early-s
- GlobeNewswire
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
Primary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Press Program and the EHA Plenary SessionLatest data from the Kisqali®* NATALEE trial, including efficacy endpoints for patients with node-negative stage II and III HR+/HER2- early breast cancerNew radioligand therapy portfolio data supporting overall platform leadership and ongoing expansion in research infrastructure an
- Thomson Reuters StreetEvents
Q1 2024 Legend Biotech Corp Earnings Call
Q1 2024 Legend Biotech Corp Earnings Call
